Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $210.5 million.

  • United Therapeutics' Capital Expenditures rose 17516.34% to $210.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $434.3 million, marking a year-over-year increase of 8209.64%. This contributed to the annual value of $246.5 million for FY2024, which is 698.78% up from last year.
  • According to the latest figures from Q3 2025, United Therapeutics' Capital Expenditures is $210.5 million, which was up 17516.34% from $62.2 million recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Capital Expenditures registered a high of $210.5 million during Q3 2025, and its lowest value of $10.6 million during Q1 2021.
  • Over the past 5 years, United Therapeutics' median Capital Expenditures value was $45.1 million (recorded in 2024), while the average stood at $57.1 million.
  • Per our database at Business Quant, United Therapeutics' Capital Expenditures surged by 47398.37% in 2021 and then crashed by 4405.1% in 2022.
  • United Therapeutics' Capital Expenditures (Quarter) stood at $70.6 million in 2021, then tumbled by 44.05% to $39.5 million in 2022, then soared by 99.24% to $78.7 million in 2023, then rose by 10.17% to $86.7 million in 2024, then skyrocketed by 142.79% to $210.5 million in 2025.
  • Its Capital Expenditures stands at $210.5 million for Q3 2025, versus $62.2 million for Q2 2025 and $74.9 million for Q1 2025.